Bipartisan INSULIN Act Seeks to Cap Monthly Costs at $35 for Patients

A new bipartisan bill in the U.S. aims to lower the cost of insulin for millions of patients. The INSULIN Act would cap monthly expenses at $35 for those with private insurance. Yet despite growing support, the proposal faces challenges in Congress.

The financial burden of insulin remains heavy for many families. Last week, a Mississippi toddler's one-month supply of vials and three-month backup pens cost his parents $194. Prices continue to vary widely, leaving some patients paying hundreds of dollars each month out of pocket. The INSULIN Act was introduced by Sens. Jeanne Shaheen, D-N.Maine, Raphael Warnock, D-Ga., Susan Collins, R-Maine, and John Kennedy, R-La. If passed, it would also launch a pilot program to provide cheaper insulin to uninsured Americans in 10 states. However, the bill's progress is uncertain due to concerns over funding and competing legislative priorities.

More than half of U.S. states have already taken action by setting insulin co-pay caps. These limits range from $25 to $100 per month for patients with state-regulated insurance plans. Still, not all Americans benefit from these measures, as coverage gaps remain.

Major insulin manufacturers have recently reduced prices, but these cuts do not reach every patient. Around 8.1 million people in the U.S. rely on insulin, including over 2 million with Type 1 diabetes. For families like that of Marlee Brandon, the toddler's mother, the fear of rising costs looms large as her son grows older and his insulin needs increase. The INSULIN Act could bring relief to millions struggling with high insulin costs. Yet its future depends on overcoming political and financial obstacles in Congress. Without further action, many patients will continue facing steep monthly expenses for a life-saving medication.